Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study [PDF]
Biomedicines, 2022 Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation.
Jose M. Huguet +11 more
doaj +4 more sources
CT-P13: design, development, and place in therapy [PDF]
Drug Design, Development and Therapy, 2017 Tommaso Gabbani,1 Simona Deiana,2 Vito Annese3 1Gastroenterology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, 2Division of Gastroenterology, AOU Careggi University Hospital, Florence, Italy; 3Gastroenterology Department, Valiant ...
Gabbani T, Deiana S, Annese V
doaj +5 more sources
Outcomes of an Intravenous to Subcutaneous Infliximab (CT‐P13) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study [PDF]
ACR Open RheumatologyObjectives To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV‐IFX) to subcutaneous infliximab (SC‐IFX, CT‐P13) in patients with Takayasu arteritis (TA). Methods We conducted a prospective,
Luca Iorio +6 more
doaj +3 more sources
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials [PDF]
Arthritis Research & Therapy, 2021 Background A subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It may offer improved efficacy versus intravenous (IV) infliximab formulations. Methods A
Bernard Combe +12 more
doaj +2 more sources
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants [PDF]
Clinical and Translational ScienceCT‐P13, a biosimilar of infliximab, is used to treat inflammatory diseases that arise from immune system complications, resulting in excessive and persistent inflammation.
Ye Chan Park +6 more
doaj +2 more sources
Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics [PDF]
مجلة كلية الطب, 2023 Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil +2 more
doaj +3 more sources
Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. [PDF]
Crohns Colitis 360, 2022 Background: Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking.
Pierik MJ +11 more
europepmc +3 more sources
Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series [PDF]
Clinical Case Reports, 2022 The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased ...
Sooraj Vijayan +2 more
doaj +2 more sources
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis [PDF]
BMC GastroenterologyBackground Since 2015, an infliximab biosimilar, CT-P13, has been approved for commercial use in many countries, easing the economic burden borne by society and patients.
Xinyue Hu +6 more
doaj +2 more sources
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study [PDF]
Clinical and Translational Science, 2022 Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and ...
Stefano Mazza +21 more
doaj +2 more sources